Parkinson's disease - Staging Hoehn & Yahr 1 to 3.
Conditions
Interventions
Intervention group: Twenty-five patients with Parkinson's disease, with Hoehn & Yahr staging from 1 to 3, will receive power trainingwith elastic bands and resistance tubes twice a week for 12 weeks.
E02.760.169.063.500.387
I02.233.332
Sponsors
Faculdade de Medicina da Universidade Federal do Ceará
Eligibility
Age
40 Years to 90 Years
Inclusion criteria
Inclusion criteria: Diagnosis of Parkinson’s disease according to the UK PD Brain Bank Diagnostic Criteria; Stages of 1 to 3 according to the modified Hoehn & Yarh scale; Stable antiparkinsonian medication regime for at least 4 weeks before the intervention; Literate; Independent in basic daily living activities according to SE higher or equal to 80%; Age of 40 years or more; Be a resident of Fortaleza.
Exclusion criteria
Exclusion criteria: BMI greater than 40 and less than 20; Diagnosis of Chron's Disease and Ulcerative Colitis; Diagnosis of Multiple Sclerosis, ADEM, Parkinsonism plus, cerebrovascular disease with motor sequelae, Guilliam-Barre; Dementia syndrome of any etiology according to MSD-V; Schizophrenia with hospitalization or psychotic episode or suicidal ideation in the last 6 months; Bipolar affective disorder with hospitalization or episode of mania or episode of hypomania or episode of depression in the last 6 months; Depression with hospitalization or suicidal ideation or psychotic episode in the last 6 months; Myocardial infarction with or without ST elevation in the last 12 months; Myocardial revascularization surgery or percutaneous anglioplasty in the last 12 months; Uncontrolled arrhythmia; Severe or oxygen dependent COPD; Cardiac insufficiency with reduced functional class III or IV; Resting Blood Pressure greater than or equal to 160 x 100 mmHg; Implantable cardioversion defibrillator (ICD); Severe chronic kidney disease (Creatinine clearance less than 30ml/min); Proliferative retinopathy secondary to diabetes; Peripheral neuropathy with motor impairment; Moderate to severe hearing impairment (inability to maintain a dialogue or need for lip reading); Moderate to severe visual impairment (minimum visual acuity 20/70 - Snellen); Cancer in activity or in treatment; History of conventional surgery or DBS for Parkinson's disease; Alcohol consumption greater than 14 drinks per week; Live with people who participate in the same study; Thromboembolism without anticoagulation regimen; Significant weight loss (10% of usual weight) in the last 6 months; Lack of family support to participate in the study; Bariatric surgery history; Exercise at moderate intensity for at least 3 x week; Glycated hemoglobin higher than 12.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Superior bradykinesia improvement in the exercise group is expected through the method of assessing bradykinesia sub-scores of the motor UPDRS. The bradykinesia sub-scores of the upper limbs will be obtained by adding the items 23, 24 and 25 of the UPDRS motor exam; while a subset of bradykinesia in the lower limbs will be the sum of items 26, 27, 29 and 31 of the UPDRS motor exam;Superior improvement in Functional Physical Performance is expected in the exercise group that will be assessed using the Short Physical Performance Battery (SPPB), which combines results of gait speed, sitting and standing time and balance tests | — |
Secondary
| Measure | Time frame |
|---|---|
| Superior benefit of parkinsonian motor and non-motor symptoms in the exercise group is expected through the total score of the UPDRS in the exercise group with reduction in the score of the base measure to one week after the intervention;Higher quality of life benefit is expected through the PDQ-39 in the exercise group with reduction in the scores from baseline measure to one week after the intervention;Superior benefit of sleep quality is expected through the Pittsburgh Sleep Quality Index (IQSP) in the exercise group with reduction in the scores from baseline measure for one week after the intervention;Superior benefit in daytime sleepiness is expected through the Epworth Sleepiness Scale (ESE) in the exercise group with a reduction in the score from baseline measure for one week after the intervention;Superior sleep benefit is expected using the Parkinson's Disease Sleep Rating Scale (PDSS) in the exercise group with increasement of scores from baseline to one week after the intervention;Superior benefit in behavioral sleep disorder is expected through the REM sleep disorders screening questionnaire - brazilian version (QRDCSR-BR) in the exercise group with reduction of score from the baseline measure compared to one week after the intervention;A higher benefit is expected in the rate of respiratory disorders in the exercise group, with a reduction in the score of the baseline measure compared to one week after the intervention;Superior benefit in the atony of the chin muscle in the REM sleep phase is expected through polysomnography with increasement from baseline measure for one week after the intervention;A higher benefit in sleep quality is expected through polysomnography in the exercise group with an increase in the deeper phases of sleep (N3 and REM), a decrease in the superficial phase (N1) from baseline measure to one week after the intervention;Superior benefit in sleep latency, total sleep time, frequency of awakening is expected through actigraph pa | — |
Countries
Brazil
Outcome results
None listed